Cormorant Asset Management
Latest statistics and disclosures from Cormorant Asset Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are TPTX, Atea Pharmaceuticals, QQQ, XBI, SPY, and represent 28.19% of Cormorant Asset Management's stock portfolio.
- Added to shares of these 10 stocks: Atea Pharmaceuticals (+$260M), QQQ (+$235M), Olema Pharmaceuticals (+$148M), XBI (+$141M), C4 Therapeutics (+$80M), Bioatla (+$75M), Tarsus Pharmaceuticals (+$70M), Praxis Precision Medicines I (+$58M), FMTX (+$38M), Aligos Therapeutics (+$35M).
- Started 24 new stock positions in IMV, XFOR, Bioatla, Atea Pharmaceuticals, Tarsus Pharmaceuticals, NVUS, QQQ, Foghorn Therapeutics, Miragen Therapeutics, Praxis Precision Medicines I. Silverback Therapeutics, Bcls Acquisition Corp, Aligos Therapeutics, 5 01 Acquisition Corp Cl A, C4 Therapeutics, Helix Acquisition Corp, Cerevel Therapeutics Hldng I, 908 Devices, Olema Pharmaceuticals, SWTX, NTLA, Galecto, REPL, 4d Molecular Therapeutics In.
- Reduced shares in these 10 stocks: Myokardia (-$61M), EIDX (-$50M), TWST (-$39M), TRIL (-$36M), ARCT (-$30M), CCXI (-$28M), GLPG (-$19M), CRSP (-$15M), OMER (-$14M), SRNE (-$14M).
- Sold out of its positions in AMRN, ARCT, AVEO, EIDX, GLPG, FIXX, KZR, Myokardia, OTLKW, TRIL.
- Cormorant Asset Management was a net buyer of stock by $936M.
- Cormorant Asset Management has $4.2B in assets under management (AUM), dropping by 61.58%.
Tip: Access up to 7 years of quarterly data
Positions held by Cormorant Asset Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Cormorant Asset Management
Companies in the Cormorant Asset Management portfolio as of the December 2020 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Turning Point Therapeutics I (TPTX) | 6.9 | $292M | -2% | 2.4M | 121.85 | |
| Atea Pharmaceuticals | 6.2 | $260M | NEW | 6.4M | 40.53 | |
| Invesco Qqq Tr Unit Ser 1 Put Option (QQQ) | 5.6 | $235M | NEW | 750k | 313.74 | |
| Spdr Ser Tr S&p Biotech Put Option (XBI) | 5.0 | $211M | +200% | 1.5M | 140.78 | |
| Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY) | 4.4 | $187M | 500k | 373.88 | ||
| Bridgebio Pharma (BBIO) | 3.8 | $161M | 2.3M | 71.11 | ||
| Forma Therapeutics Hldgs SHS (FMTX) | 3.7 | $156M | +31% | 4.5M | 34.90 | |
| Olema Pharmaceuticals | 3.5 | $148M | NEW | 3.2M | 46.37 | |
| Apellis Pharmaceuticals (APLS) | 2.5 | $107M | 1.9M | 57.20 | ||
| Revolution Medicines (RVMD) | 2.4 | $99M | -5% | 2.5M | 39.59 | |
| Ishares Tr Russell 2000 Etf Put Option (IWM) | 2.3 | $98M | 500k | 196.06 | ||
| Stoke Therapeutics (STOK) | 2.1 | $89M | -6% | 1.4M | 61.93 | |
| Y Mabs Therapeutics (YMAB) | 2.0 | $82M | +18% | 1.7M | 49.51 | |
| C4 Therapeutics Com Stk | 1.9 | $80M | NEW | 2.5M | 32.14 | |
Setup an alertCormorant Asset Management will file the next quarterly 13-HR in about 3 months. Would you like to be notified? |
||||||
| Alx Oncology Hldgs (ALXO) | 1.8 | $76M | -9% | 882k | 86.20 | |
| Beam Therapeutics (BEAM) | 1.8 | $76M | +16% | 924k | 81.64 | |
| Bioatla | 1.8 | $75M | NEW | 2.3M | 32.90 | |
| Rocket Pharmaceuticals (RCKT) | 1.8 | $75M | 1.4M | 54.84 | ||
| Chemocentryx (CCXI) | 1.8 | $74M | -27% | 1.2M | 61.92 | |
| Immunovant (IMVT) | 1.7 | $72M | -4% | 1.6M | 46.19 | |
| Omeros Corporation (OMER) | 1.7 | $71M | -16% | 5.0M | 14.29 | |
| Mirati Therapeutics (MRTX) | 1.7 | $71M | +18% | 325k | 219.64 | |
| Tarsus Pharmaceuticals | 1.7 | $70M | NEW | 1.7M | 40.81 | |
| Avidity Biosciences Ord (RNA) | 1.5 | $63M | 2.5M | 25.52 | ||
| Reata Pharmaceuticals Cl A (RETA) | 1.5 | $62M | +11% | 500k | 123.62 | |
| Praxis Precision Medicines I | 1.4 | $58M | NEW | 1.1M | 53.75 | |
| Zymeworks (ZYME) | 1.3 | $57M | +4% | 1.2M | 47.26 | |
| Acceleron Pharma (XLRN) | 1.3 | $54M | -15% | 425k | 127.94 | |
| Igm Biosciences (IGMS) | 1.3 | $53M | +166% | 600k | 88.29 | |
| Viela Bio (VIE) | 1.2 | $51M | -9% | 1.4M | 35.97 | |
| Myovant Sciences (MYOV) | 1.1 | $47M | -20% | 1.7M | 27.62 | |
| Biohaven Pharmaceutical Holding (BHVN) | 0.9 | $36M | -15% | 425k | 85.71 | |
| Axonics Modulation Technolog (AXNX) | 0.8 | $35M | 693k | 49.92 | ||
| Aligos Therapeutics | 0.8 | $35M | NEW | 1.3M | 27.21 | |
| Twist Bioscience Corp (TWST) | 0.8 | $32M | -55% | 225k | 141.29 | |
| Sorrento Therapeutics Com New (SRNE) | 0.7 | $31M | -30% | 4.5M | 6.83 | |
| Crispr Therapeutics Namen Akt (CRSP) | 0.7 | $31M | -33% | 200k | 153.11 | |
| 908 Devices | 0.7 | $30M | NEW | 545k | 54.10 | |
| Galecto | 0.6 | $27M | NEW | 2.2M | 12.30 | |
| Zai Lab Adr (ZLAB) | 0.6 | $26M | 189k | 135.34 | ||
| Blueprint Medicines (BPMC) | 0.6 | $25M | -18% | 225k | 112.15 | |
| Cabaletta Bio (CABA) | 0.6 | $24M | -7% | 1.9M | 12.48 | |
| Silverback Therapeutics | 0.6 | $23M | NEW | 500k | 46.34 | |
| Biontech Se Sponsored Ads (BNTX) | 0.5 | $22M | -15% | 275k | 81.52 | |
| Agenus Com New (AGEN) | 0.5 | $22M | -17% | 7.0M | 3.18 | |
| Tokai Pharmaceuticals (NVUS) | 0.5 | $21M | NEW | 1.4M | 15.09 | |
| Kura Oncology (KURA) | 0.5 | $21M | +30% | 650k | 32.66 | |
| Foghorn Therapeutics | 0.5 | $20M | NEW | 1.0M | 20.27 | |
| Akero Therapeutics (AKRO) | 0.5 | $19M | -13% | 743k | 25.80 | |
| Inspire Med Sys (INSP) | 0.4 | $19M | -16% | 100k | 188.09 | |
| Albireo Pharma (ALBO) | 0.4 | $19M | -28% | 500k | 37.51 | |
| Otonomy (OTIC) | 0.4 | $17M | -19% | 2.6M | 6.47 | |
| Ascendis Pharma A/s Sponsored Adr (ASND) | 0.4 | $17M | -20% | 100k | 166.78 | |
| Intellia Therapeutics Put Option (NTLA) | 0.4 | $16M | NEW | 300k | 54.40 | |
| Axsome Therapeutics (AXSM) | 0.4 | $16M | -20% | 200k | 81.47 | |
| Tcr2 Therapeutics Inc cs (TCRR) | 0.4 | $16M | -16% | 500k | 30.93 | |
| Anaptysbio Inc Common (ANAB) | 0.3 | $14M | 650k | 21.50 | ||
| Pliant Therapeutics (PLRX) | 0.3 | $14M | 611k | 22.72 | ||
| Sarepta Therapeutics (SRPT) | 0.3 | $12M | -17% | 70k | 170.49 | |
| Deciphera Pharmaceuticals (DCPH) | 0.3 | $11M | -20% | 200k | 57.07 | |
| Repare Therapeutics Ord (RPTX) | 0.2 | $10M | -13% | 300k | 34.30 | |
| Health Sciences Acq Corp 2 Ord Shs (HSAQ) | 0.2 | $10M | 800k | 12.81 | ||
| Iteos Therapeutics (ITOS) | 0.2 | $10M | -14% | 300k | 33.82 | |
| Insmed Com Par $.01 (INSM) | 0.2 | $10M | -14% | 300k | 33.29 | |
| Akouos (AKUS) | 0.2 | $9.9M | 500k | 19.83 | ||
| Theravance Biopharma (TBPH) | 0.2 | $9.8M | -15% | 550k | 17.77 | |
| Harpoon Therapeutics (HARP) | 0.2 | $9.5M | 571k | 16.61 | ||
| Bctg Acquisition Corp (BCTG) | 0.2 | $9.2M | 800k | 11.44 | ||
| Springworks Therapeutics (SWTX) | 0.2 | $9.1M | NEW | 125k | 72.52 | |
| Uniqure Nv SHS (QURE) | 0.2 | $9.0M | -23% | 250k | 36.13 | |
| Argenx Se Sponsored Adr (ARGX) | 0.2 | $8.8M | -25% | 30k | 294.10 | |
| Protara Therapeutics Com Stk (TARA) | 0.2 | $8.5M | -22% | 350k | 24.21 | |
| 4d Molecular Therapeutics In | 0.2 | $8.3M | NEW | 200k | 41.45 | |
| Gossamer Bio (GOSS) | 0.2 | $8.2M | +241% | 848k | 9.67 | |
| Quotient SHS (QTNT) | 0.2 | $7.8M | -25% | 1.5M | 5.21 | |
| Allakos (ALLK) | 0.2 | $7.0M | -33% | 50k | 140.00 | |
| Therapeutics Acquisition Cor Com Cl A (RACA) | 0.2 | $7.0M | 500k | 13.95 | ||
| Morphic Hldg (MORF) | 0.2 | $6.7M | -20% | 200k | 33.55 | |
| Merus N V (MRUS) | 0.1 | $6.1M | -18% | 350k | 17.53 | |
| Genetron Hldgs Ads (GTH) | 0.1 | $5.6M | -20% | 400k | 14.00 | |
| Bcls Acquisition Corp Com Cl A | 0.1 | $5.5M | NEW | 500k | 11.03 | |
| Fs Dev Corp Com Cl A (FSDC) | 0.1 | $5.5M | 500k | 11.00 | ||
| 5 01 Acquisition Corp Com Cl A | 0.1 | $5.1M | NEW | 500k | 10.17 | |
| Eiger Biopharmaceuticals (EIGR) | 0.1 | $4.9M | -11% | 400k | 12.29 | |
| Vesper Healthcare Acqstn Cor Unit 99/99/9999 (VSPRU) | 0.1 | $4.8M | 400k | 12.12 | ||
| Replimune Group (REPL) | 0.1 | $4.8M | NEW | 125k | 38.15 | |
| Helix Acquisition Corp Com Cl A | 0.1 | $4.7M | NEW | 430k | 11.03 | |
| Atreca Cl A Com (BCEL) | 0.1 | $4.7M | 294k | 16.15 | ||
| Autolus Therapeutics Spon Ads (AUTL) | 0.1 | $3.8M | 422k | 8.94 | ||
| Kadmon Hldgs (KDMN) | 0.1 | $3.5M | -15% | 850k | 4.15 | |
| Avrobio Ord (AVRO) | 0.1 | $3.4M | 244k | 13.94 | ||
| Panacea Acquisition Corp Unit 99/99/9999 (PANA.U) | 0.1 | $3.2M | 250k | 12.76 | ||
| Tricida (TCDA) | 0.1 | $3.0M | -41% | 428k | 7.05 | |
| Precision Biosciences Ord (DTIL) | 0.1 | $2.9M | 347k | 8.34 | ||
| Cardiff Oncology (CRDF) | 0.1 | $2.7M | -14% | 150k | 17.99 | |
| Arena Pharmaceuticals Com New (ARNA) | 0.0 | $1.5M | -33% | 20k | 76.85 | |
| Miragen Therapeutics Com New | 0.0 | $1.5M | NEW | 93k | 16.45 | |
| Orchard Therapeutics Ads (ORTX) | 0.0 | $1.1M | 257k | 4.32 | ||
| Fate Therapeutics (FATE) | 0.0 | $909k | -33% | 10k | 90.90 | |
| Cerevel Therapeutics Hldng I *w Exp 06/09/202 | 0.0 | $753k | NEW | 133k | 5.65 | |
| Imv (IMV) | 0.0 | $716k | NEW | 234k | 3.05 | |
| Nektar Therapeutics (NKTR) | 0.0 | $680k | -20% | 40k | 17.00 | |
| X4 Pharmaceuticals (XFOR) | 0.0 | $669k | NEW | 104k | 6.43 | |
| Minerva Neurosciences (NERV) | 0.0 | $468k | -16% | 200k | 2.34 | |
Past Filings by Cormorant Asset Management
SEC 13F filings are viewable for Cormorant Asset Management going back to 2013
- Cormorant Asset Management 2020 Q4 filed Feb. 16, 2021
- Cormorant Asset Management 2020 Q3 filed Nov. 16, 2020
- Cormorant Asset Management 2020 Q2 filed Aug. 14, 2020
- Cormorant Asset Management 2020 Q1 filed May 15, 2020
- Cormorant Asset Management 2019 Q4 filed Feb. 14, 2020
- Cormorant Asset Management 2019 Q3 filed Nov. 14, 2019
- Cormorant Asset Management 2019 Q2 filed Aug. 14, 2019
- Cormorant Asset Management 2019 Q1 filed May 15, 2019
- Cormorant Asset Management 2018 Q4 filed Feb. 14, 2019
- Cormorant Asset Management 2018 Q3 filed Nov. 14, 2018
- Cormorant Asset Management 2018 Q2 filed Aug. 14, 2018
- Cormorant Asset Management 2018 Q1 filed May 15, 2018
- Cormorant Asset Management 2017 Q4 filed Feb. 14, 2018
- Cormorant Asset Management 2017 Q3 filed Nov. 14, 2017
- Cormorant Asset Management 2017 Q2 filed Aug. 14, 2017
- Cormorant Asset Management 2017 Q1 filed May 15, 2017